Seluna
AI-powered software for diagnosing and managing pediatric sleep disorders, particularly obstructive sleep apnea.
Cover Block
Publicly reported
| Field | Detail |
|---|---|
| Name | Seluna |
| Tagline | AI-powered software for diagnosing and managing pediatric sleep disorders, particularly obstructive sleep apnea. |
| Headquarters | Glasgow, United Kingdom [Crunchbase] |
| Founded | 2022 [Crunchbase] |
| Stage | Seed [Vestbee, August 2025] |
| Business model | SaaS |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | Western Europe |
| Growth profile | Venture Scale |
| Founding team | Co-Founders (2), Dr Scott Black and Dr Yola Jones [Startup Grind Glasgow, August 2025] |
| Funding label | Seed |
| Total disclosed | Approximately $825,000 [Vestbee, August 2025] |
Links
Publicly reported
- Website: https://seluna.co.uk
Summary and Signal
PUBLIC Seluna is building AI-based software to interpret pediatric sleep studies, a narrow but consequential clinical workflow that has attracted investor attention because the company is now moving from early product claims into formal validation activity with NHS-linked partners [EU-Startups, August 2025] [BioWorld, September 2026]. Founded in Glasgow in 2022 by Dr Scott Black and Dr Yola Jones, the company is positioned around childhood sleep-disordered breathing, with public coverage consistently describing a pediatric-first approach rather than adapting adult sleep diagnostics to children [Digital Health, August 2025] [Crunchbase].
The product, according to sector coverage, is a software as a medical device intended to automate interpretation of pediatric sleep studies by identifying and classifying digital biomarkers of sleep-disordered breathing, with the stated goal of helping clinicians diagnose and prioritize treatment for children who need faster intervention [EU-Startups, August 2025] [BioWorld, September 2026] [Vestbee, August 2025]. That differentiation matters if it holds up in practice: the public case for Seluna rests less on generalized AI claims and more on whether a child-specific workflow can produce more consistent readings and support home or hospital-based testing without sacrificing clinical accuracy [Digital Health, August 2025] [interface-online.org.uk].
The founding team is publicly identified as Dr Scott Black, CEO, and Dr Yola Jones, CTO, while Jones is also listed by the University of Edinburgh as a PhD student, which gives some support to the company's technical and research orientation even though detailed prior operator histories are not well documented in the retrieved sources [Startup Grind Glasgow, August 2025] [The University of Edinburgh]. Public reporting also suggests Seluna has collaborated with NHS Greater Glasgow and Clyde and launched a 500-patient validation study at the Royal Hospital for Children in Glasgow, which is the most tangible operating milestone visible so far [Startup Grind Glasgow, August 2025] [Tech.eu, August 28, 2025] [BioWorld, September 2026].
On financing, the cleanest confirmed round in the source set is an August 2025 seed financing reported at about $825,000, led by STAC Invest, with Gabriel Investment Syndicate, Scottish Enterprise, and the University of Strathclyde also named as backers across coverage [Vestbee, August 2025] [Digital Health, August 2025].
One source, partially checked -- Core company identity, funding, and validation-study claims are supported by multiple public sources, but several product and team details remain partly company-linked or only singly corroborated.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | SaaS |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | Seed, total disclosed approximately $825,000 |
Company Overview
PUBLIC
Seluna presents as an early-stage Glasgow medtech built around a narrow clinical problem rather than a broad wellness pitch. Public company profiles describe it as a Glasgow, United Kingdom-based business founded in 2022, operating in software for paediatric sleep diagnostics, with Dr Scott Black and Dr Yola Jones listed as co-founders [Crunchbase] [Seluna].
The public record on corporate formation is still thin, so the cleaner read is chronological. The company profile on Crunchbase places the founding in 2022 [Crunchbase]. By August 2025, Seluna was publicly tied to a new seed financing that brought in STAC Invest alongside Gabriel Investment Syndicate, Scottish Enterprise, and the University of Strathclyde, according to company-linked reporting on its NHS study announcement and public company database entries [Crunchbase] [Seluna].
A second milestone is the move from product framing into clinical validation. On its website, Seluna said it launched an NHS study intended to advance paediatric sleep diagnosis, and that announcement aligns with later public descriptions of the company as a software-as-a-medical-device effort focused on childhood sleep disorders [Seluna] [Crunchbase]. The available public materials do not establish a legal entity name beyond the operating brand.
No independent source found -- This section relies on Crunchbase and the company website, with key operating details and milestones materially supported by company-controlled sources.
The Product and the Stack
MIXED
Seluna is building software for a narrow clinical workflow that is easy to describe and harder to execute well: interpreting paediatric sleep studies quickly enough to help clinicians triage children with suspected sleep-disordered breathing [Digital Health, August 2025] [EU-Startups, August 2025]. Public reporting describes the product as a machine learning-enabled software as a medical device that automatically scores paediatric sleep studies by identifying and classifying digital biomarkers, with the stated aim of helping doctors diagnose childhood sleep disorders and prioritise treatment for children who need urgent intervention [EU-Startups, August 2025] [BioWorld, September 2026]. That focus on children matters because several reports frame Seluna's wedge as adaptation to paediatric use cases rather than a generic sleep analytics layer repackaged for hospitals [Digital Health, August 2025] [Vestbee, August 2025].
The disclosed product scope extends beyond software interpretation alone, although the evidence is less consistent on how far the hardware component is already commercial versus still validation-stage. Company and sector coverage says Seluna combines its SaMD with a child-friendly cardiorespiratory wearable to support home sleep testing, while a 2026 BioWorld report centers more narrowly on validation of the diagnostic software itself [Seluna] [BioWorld, September 2026]. The same body of reporting ties the product to NHS collaboration and a 500-patient clinical validation study at the Royal Hospital for Children in Glasgow, which is relevant because for a diagnostic workflow the technical claim and the clinical proof point are inseparable [Tech.eu, August 2025] [Vestbee, August 2025]. What is still not established in the public record is regulatory clearance, paid deployment at scale, or enough technical disclosure to assess model architecture, training data composition, or workflow integration in detail [BioWorld, September 2026] [Startup Grind Glasgow, August 2025].
One source, partially checked -- Product positioning is corroborated across Digital Health, EU-Startups, Vestbee, Tech.eu, BioWorld, and the company site, but several capability details remain company-described or lightly specified in public sources.
The Market They Are Entering
PUBLIC
The market matters now because pediatric sleep diagnostics sits at the intersection of two durable pressures, rising demand for specialist care and health systems' need to shorten interpretation bottlenecks with software rather than staff expansion.
The available public record does not support a direct TAM, SAM, or SOM estimate for Seluna's specific category, and the prudent way to size the opportunity is through adjacent public markets rather than invented precision. What is documented is the problem definition: Seluna is targeting software that helps clinicians interpret pediatric sleep studies and prioritize treatment for childhood sleep disorders, with NHS-linked validation activity at the Royal Hospital for Children in Glasgow [BioWorld, September 2026] [Tech.eu, August 2025]. That places the company across at least three overlapping markets: sleep diagnostics, pediatric medtech, and software as a medical device for hospital workflows.
A narrow reading suggests the immediate commercial wedge is not consumer sleep wellness but provider-side diagnostic infrastructure. Sector coverage describes the product as machine-learning software for diagnosing and managing childhood sleep apnoea, aimed at automating interpretation of pediatric sleep studies for clinicians and health services [Digital Health, August 2025] [Vestbee, August 2025]. That matters for market construction, because the relevant budget owner is more likely a hospital, children's specialty center, or public health service than an individual patient.
The public evidence is stronger on demand drivers than on market size. Multiple reports describe a validation study involving 500 patients at the Royal Hospital for Children in Glasgow, which signals that the bottleneck Seluna is addressing is clinically material enough to justify prospective study work inside a pediatric care setting [Vestbee, August 2025] [Tech.eu, August 2025]. The recurring framing across publishers is speed and consistency in interpreting sleep studies and prioritizing urgent cases, which aligns with a workflow pain point rather than a discretionary software add-on [BioWorld, September 2026] [Digital Health, August 2025].
| Market lens | What public sources support | Relevance to Seluna |
|---|---|---|
| Pediatric sleep diagnostics | Clinical validation in a 500-patient study at the Royal Hospital for Children in Glasgow [Vestbee, August 2025] [Tech.eu, August 2025] | Closest fit to the company's stated use case |
| Hospital diagnostic workflow software | Product described as software as a medical device supporting clinicians in diagnosis and triage [BioWorld, September 2026] [Digital Health, August 2025] | Suggests provider budget and compliance-led sales motion |
| Home sleep testing and wearables | Reporting says Seluna combines SaMD with a child-friendly cardiorespiratory wearable for home sleep testing [BioWorld, September 2026] | Expands the opportunity beyond in-lab interpretation if validated |
from the available market evidence is that Seluna appears to be pursuing a defined clinical workflow wedge inside a broader diagnostic software market, but public sourcing is still too thin to attach a defensible dollar figure to that wedge. For now, the market case rests more on documented care friction and institutional interest than on published category sizing.
Adjacent markets deserve attention because they may shape adoption faster than the core sleep-apnoea segment. The company is described not only as a diagnostic software provider but, in later coverage, as combining software with a child-friendly cardiorespiratory wearable for home sleep testing [BioWorld, September 2026]. If that product scope holds through validation and regulatory work, Seluna would sit near substitute pathways such as general respiratory monitoring, home diagnostics, and broader pediatric remote assessment. That widens the theoretical opportunity, but it also introduces more complex procurement and evidence requirements than a pure interpretation layer.
Regulation is likely to be a gating factor rather than a background consideration. Public sources repeatedly characterize the product as software as a medical device, and company-linked fundraising coverage connects the recent capital to validation studies and progress toward formal clinical trials [Vestbee, August 2025] [Tech.eu, August 2025] [BioWorld, September 2026]. In practical terms, that means market entry is unlikely to look like standard SaaS expansion. Evidence generation, hospital trust, and regulatory pathway execution will shape sales velocity at least as much as product usability.
The macro setting is broadly supportive for solutions that can move diagnosis closer to the home while preserving clinical reliability. BioWorld's reporting ties Seluna's proposition to faster diagnosis and treatment prioritization, while startup and sector coverage frames the benefit as reducing delays and inconsistency in pediatric sleep-study interpretation [BioWorld, September 2026] [EU-Startups, August 2025] [Startup Grind Glasgow, August 2025]. That is a credible tailwind in publicly funded systems under staffing pressure, though the current record does not yet show paid deployment or procurement scale.
One source, partially checked -- Section is grounded in named publisher coverage from BioWorld, Tech.eu, Vestbee, Digital Health, EU-Startups, and Startup Grind Glasgow, but it does not include third-party TAM/SAM/SOM figures for Seluna's exact market.
The Competitive Field
MIXED Seluna appears to be positioning itself less against a clearly disclosed startup peer set and more against the established pediatric sleep-diagnostics workflow inside hospitals, where interpretation capacity, not just data capture, is the bottleneck [Digital Health, August 2025] [Vestbee, August 2025] [BioWorld, September 2026].
The public record supports three competitive buckets, even if it does not name direct venture-backed rivals. First are incumbent clinical pathways, meaning pediatric sleep labs and hospital teams that review sleep studies through existing processes. That is the baseline Seluna is trying to displace or augment, with software intended to automate interpretation of pediatric sleep studies and help clinicians prioritize treatment for childhood sleep disorders [Digital Health, August 2025] [EU-Startups, August 2025] [BioWorld, September 2026]. Second are adult-oriented sleep diagnostics workflows, which multiple reports describe as a poor fit for children and therefore the contrast case for Seluna's product design [Digital Health, August 2025] [Startup Grind Glasgow, August 2025]. Third are adjacent home-testing and wearable approaches, implied by reporting that Seluna combines software with a child-friendly cardiorespiratory wearable and is pursuing validation in clinical settings rather than as a direct-to-consumer sleep product [BioWorld, September 2026] [Seluna].
The edge visible today is narrow but real. Seluna's strongest disclosed differentiator is pediatric specificity, paired with access to NHS-linked validation environments including NHS Greater Glasgow and Clyde and a 500-patient study at the Royal Hospital for Children in Glasgow [Startup Grind Glasgow, August 2025] [Vestbee, August 2025] [Tech.eu, August 28, 2025] [BioWorld, September 2026]. If that work produces clinically credible performance data, the moat could come from labeled pediatric sleep datasets, workflow fit for child patients, and trust with hospital buyers. That edge is still perishable rather than locked in, because the public sources do not yet establish regulatory clearance, paid deployment at scale, or a distribution channel beyond early NHS collaborations [BioWorld, September 2026] [Vestbee, August 2025].
The exposure is just as clear. Incumbent hospital pathways already own the clinician relationship, the reimbursement context, and the diagnostic setting, which means Seluna is not replacing a vacuum but asking providers to change a medical workflow [Startup Grind Glasgow, August 2025] [BioWorld, September 2026]. The adjacent substitute is also meaningful: if conventional sleep labs or broader medtech vendors can adapt existing tools for pediatric use faster than Seluna can complete validation and move through the software-as-a-medical-device path, then Seluna's product advantage compresses into a feature rather than a standalone platform [Digital Health, August 2025] [BioWorld, September 2026]. Public reporting also does not show that Seluna owns a referral channel, a payer relationship, or a broad commercial sales motion, so its route to market remains heavily tied to provider adoption.
The most plausible 18-month scenario is a contest between validated specialist software and entrenched clinical process. Seluna is the likely winner if the Royal Hospital for Children study and related NHS work translate into publishable evidence, smoother triage, and a credible path toward routine clinical use, because pediatric focus is the company's clearest point of separation today [Vestbee, August 2025] [Tech.eu, August 28, 2025] [BioWorld, September 2026]. The incumbent workflow is the likely loser if hospitals decide that manual interpretation is too slow or inconsistent for rising pediatric demand. The reverse case is also straightforward: incumbent hospital pathways remain the winner if validation takes longer than expected or if buyers conclude that existing systems are sufficient once staffing and process are improved, in which case Seluna's specialist positioning may struggle to convert technical promise into procurement momentum [Startup Grind Glasgow, August 2025] [BioWorld, September 2026].
One source, partially checked -- Competitive analysis is grounded in named public sources on Seluna's positioning and clinical context, but the public record does not identify named direct competitors or independently verify durable commercial advantages.
Opportunity
PUBLIC The prize here is not a better workflow tool for one sleep lab, but a shot at becoming part of the diagnostic infrastructure for pediatric sleep medicine if Seluna can turn validation data into clinical adoption and, eventually, standard-of-care software across hospital systems [BioWorld, September 2026] [EU-Startups, August 2025].
The largest plausible outcome is fairly specific. Seluna could become the default software layer used to interpret pediatric sleep studies and triage treatment urgency, starting in the NHS and extending into other pediatric care settings that still rely on adult-derived processes for children [Digital Health, August 2025] [Vestbee, August 2025]. That is reachable, rather than merely aspirational, because the company is not presenting a consumer wellness angle or a broad AI-in-healthcare pitch. The public record points to a defined clinical problem, a software-as-a-medical-device approach, named NHS-linked validation activity, and a 500-patient study at the Royal Hospital for Children in Glasgow, all of which suggest a real path from technical promise to institutional use if the evidence holds up [Tech.eu, August 28, 2025] [Vestbee, August 2025] [BioWorld, September 2026].
A second reason the upside is meaningful is that Seluna appears to be building around pediatric specificity, not generic sleep analytics. Multiple reports describe conventional workflows as adult-based and position Seluna's system as designed for children, with machine learning used to identify and classify digital biomarkers in pediatric sleep data [Digital Health, August 2025] [EU-Startups, August 2025]. In health software, a narrow initial wedge can matter more than a broad product map. If a company earns trust in one high-friction diagnostic domain, adjacent expansion, such as home testing, prioritization workflows, and longitudinal management, becomes easier to underwrite than it would from a cold start [BioWorld, September 2026] [interface-online.org.uk].
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| NHS pediatric sleep standard | Seluna converts validation work into repeat use across NHS pediatric sleep pathways, becoming a common interpretation and triage layer for children's sleep studies | Strong results from the 500-patient Royal Hospital for Children study and broader NHS references in public materials [Tech.eu, August 28, 2025] [Startup Grind Glasgow, August 2025] | The company already cites NHS Greater Glasgow and Clyde collaboration, and the validation study is tied to real-world clinical use rather than lab-only development [Startup Grind Glasgow, August 2025] [Vestbee, August 2025] |
| Home diagnostics platform | Seluna extends from software interpretation into a fuller home-testing workflow built around its child-friendly cardiorespiratory wearable plus SaMD | Clinical validation that supports equivalence or practical utility for home studies, followed by hospital adoption where lab capacity is constrained [BioWorld, September 2026] [Seluna] | Public descriptions already pair the machine learning software with a child-friendly wearable for home sleep testing, which suggests a broader platform ambition beyond scoring alone [Seluna] [interface-online.org.uk] |
| Pediatric sleep data moat | Seluna becomes the best-performing specialist model stack for pediatric sleep-disordered breathing and licenses or embeds that capability into hospital and diagnostic workflows beyond Scotland | Accumulation of proprietary pediatric study data through validation and deployment, plus regulatory progress for SaMD [EU-Startups, August 2025] [Vestbee, August 2025] | The product is described as identifying and classifying digital biomarkers in pediatric sleep data, and specialist datasets in under-served populations can improve model defensibility over time if access persists [EU-Startups, August 2025] [Digital Health, August 2025] |
The compounding mechanism, if it emerges, is a clinical data and workflow flywheel. More hospital use should produce more pediatric sleep studies, which should improve model performance and confidence across edge cases, which in turn could support wider clinician trust and more pathway integration, especially if Seluna is involved early in prioritization rather than only retrospective scoring [EU-Startups, August 2025] [BioWorld, September 2026]. That flywheel is still early, but there are hints that it has started: the company has reported NHS collaboration, a named hospital validation study, and a product architecture that spans both interpretation and, at least in some public descriptions, wearable-enabled home testing [Startup Grind Glasgow, August 2025] [Tech.eu, August 28, 2025] [Seluna].
The size of the win is harder to frame because the public record here does not provide a sourced market-size benchmark or a clean listed comparable focused narrowly on pediatric sleep diagnostics. Even so, the strategic endpoint is clear enough to describe. If Seluna were to become a trusted pediatric diagnostic platform with regulatory traction, multi-site hospital adoption, and a defensible pediatric dataset, it could support venture-scale outcomes more akin to category software or specialist digital diagnostics than to a single-clinic tool vendor (scenario, not a forecast) [BioWorld, September 2026] [Vestbee, August 2025]. The evidence base is still too thin to put a disciplined valuation range on that upside in public, but the pathway to a meaningful outcome rests on something concrete: turning one validated pediatric use case into the software layer that clinicians rely on for faster, more consistent diagnosis and triage [Digital Health, August 2025] [EU-Startups, August 2025].
One source, partially checked -- This section relies on named public sources including BioWorld, Tech.eu, Vestbee, EU-Startups, Digital Health, Startup Grind Glasgow, and Seluna's own site; the upside analysis is conditional, and several product-scope details remain company-linked or single-source corroborated.
Sources
Publicly reported
[Crunchbase] Seluna | Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/seluna
[Vestbee, August 2025] STAC Invest invests £1M in three female-led healthcare startups | https://www.vestbee.com/insights/articles/stac-invest-invests-1-million
[Startup Grind Glasgow, August 2025] Startup Funding: Finding the Right Fit | https://www.startupgrind.com/events/details/startup_grind-glasgow-presents-startup-funding-finding-the-right-fit/
[EU-Startups, August 2025] Scotland's Seluna dreams big (and helps kids sleep better) with nearly €752k for AI-powered diagnosis tool | https://www.eu-startups.com/2025/08/scotlands-seluna-dreams-big-and-helps-kids-sleep-better-with-nearly-e752k-for-ai-powered-diagnosis-tool/
[BioWorld, September 2026] Seluna launches study to validate sleep diagnostic software | https://www.bioworld.com/articles/723460-seluna-launches-study-to-validate-sleep-diagnostic-software
[Digital Health, August 2025] Scottish accelerator invests £1m in female-led HealthTech startups | https://www.digitalhealth.net/2025/08/scottish-accelerator-invests-1m-in-female-led-healthtech-startups/
[interface-online.org.uk] Scottish MedTech company launches NHS study to advance paediatric sleep diagnosis | https://interface-online.org.uk/news/scottish-medtech-company-launches-nhs-study-to-advance-paediatric-sleep-diagnosis/
[The University of Edinburgh] Yola Jones | https://www.ed.ac.uk/profile/yola-jones
[Seluna] Scottish MedTech company launches NHS study to advance paediatric sleep diagnosis | https://seluna.co.uk/scottish-medtech-company-launches-nhs-study-to-advance-paediatric-sleep-diagnosis/
[Tech.eu, August 28, 2025] Seluna secures £650K and launches major clinical trial for childhood sleep disorder diagnostics | https://tech.eu/2025/08/28/seluna-secures-ps650k-funding-and-launches-major-clinical-trial-for-childhood-sleep-disorder-diagnostics/
Articles about Seluna
- Seluna's AI Targets a 500-Patient Trial to Decode Pediatric Sleep — The Glasgow startup has secured over £1.2 million to validate its diagnostic software for childhood obstructive sleep apnea.